The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

22 Dec 2017 11:30

RNS Number : 2392A
Concepta PLC
22 December 2017
 

22 December 2017

 

Concepta plc

 

("Concepta" or the "Company")

 

Trading update

 

Pursuant to the statement made on 6 November and 13 November 2017, Concepta plc, the UK healthcare company and developer of a proprietary platform and suite of products targeted at the mobile health market with a primary focus on women's fertility, provides shareholders today with an update on trading ahead of its 31 December 2017 year end.

 

Due to a labelling quality issue with the Company's manufacturer in China following its recent ramp up of production, the Company did not receive sufficient monitors to meet the order announced on 13 November. The majority of this order will now be delivered in January 2018. This issue, although now rectified, will have a distortion on the 2017 revenues which are now expected to be around £100,000. The Company will now recognise the majority of the revenue relating to this order in Q1 2018.

 

Orders have been increasing in the last few months of 2017 and with further new distributors likely to be appointed in the New Year the Board expects the delayed revenue referred to above to be additive to the 2018 budget. Following its recent fundraise, the Company has sufficient cash to meet its working capital requirements through 2018.

 

Erik Henau, CEO of Concepta plc said: "The team on the ground in China have been working hard over recent months to address issues identified within our supply chain as we continue to scale up production. The China team will have the support of David Darrock as Chief Operating Officer who has experience in the move from assembling products in a laboratory environment to full scale commercial manufacturing. We enforce strict quality control standards on our products and as such we have commenced a full supply chain evaluation with our suppliers and have implemented a number of measures to strengthen processes, for which we are already seeing significant improvements. Despite the impact of these issues I am confident that, following the improvements made, we are entering 2018 in a much stronger position."

 

ENDS

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Joint Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Novum Securities (Joint Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

 

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

 

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBBBDDCDDBGRD
Date   Source Headline
27th Jul 20162:28 pmRNSTR-1: Notification of major interest in shares
27th Jul 20169:41 amRNSTR-1: Notification of major interest in shares
26th Jul 20168:30 amRNSRe. Admission to AIM of Concepta PLC
26th Jul 20168:00 amRNSAdmission to AIM
25th Jul 201612:34 pmRNSResult of General Meetings and Open Offer
12th Jul 20163:30 pmRNSSchedule 1 update - Frontier Resources Intl. PLC
12th Jul 20161:45 pmRNSIssue of Equity
8th Jul 20165:00 pmRNSIssue of Circular
7th Jul 20169:30 amRNSSchedule 1 - Frontier Resources International Plc
7th Jul 20168:24 amRNSExpected Timetable of Open Offer
7th Jul 20167:00 amRNSAcquisition, Placing & Open Offer, Change of Name
7th Jul 20167:00 amRNSFundraising & AIM Admission of Direct Investment
29th Jun 20167:00 amRNSChange of Adviser
1st Jun 20161:59 pmRNSResult of AGM
6th May 20165:20 pmRNSNotice of AGM
4th May 201610:50 amRNSTotal Voting Rights
3rd May 20167:00 amRNSFinal results for year ended 31 December 2015
8th Apr 201612:49 pmRNSIssue of Equity
23rd Mar 201612:01 pmRNSCompletion of disposals
22nd Mar 20163:29 pmRNSResult of General Meeting
3rd Mar 20164:25 pmRNSPosting of Circular
3rd Mar 20167:00 amRNSDisposal and Notice of General Meeting
2nd Mar 201611:19 amRNSHolding(s) in Company
29th Feb 20164:29 pmRNSTotal Voting Rights
26th Feb 20164:40 pmRNSSecond Price Monitoring Extn
26th Feb 20164:35 pmRNSPrice Monitoring Extension
22nd Feb 20165:18 pmRNSHolding(s) in Company
17th Feb 20164:34 pmRNSCompletion of subscription and Board changes
15th Feb 201612:53 pmRNSBonus Warrant Issue - Further Update
11th Feb 20162:12 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSREPLACEMENTConditional Subscription, Board Changes
5th Feb 201610:35 amRNSConditional Subscription, Board Changes & Update
4th Feb 20164:00 pmRNSCorporate Update
26th Jan 20164:40 pmRNSSecond Price Monitoring Extn
26th Jan 20164:35 pmRNSPrice Monitoring Extension
21st Jan 201612:43 pmRNSCorporate Update
7th Jan 201610:52 amRNSCorporate Update - Zambia
6th Jan 201611:32 amRNSGeneral Meeting Result and Capital Reorganisation
31st Dec 20157:00 amRNSTotal Voting Rights
16th Dec 20153:46 pmRNSNotice of General Meeting
26th Nov 201511:12 amRNSIssue of Equity
16th Nov 20151:34 pmRNSCorporate Update
10th Nov 20155:02 pmRNSOperational Update - Oman
30th Sep 201510:06 amRNSHalf Yearly Report
8th Sep 20157:00 amRNSOperational Update
7th Aug 20154:25 pmRNSTotal Voting Rights
30th Jul 20157:00 amRNSOperational Update, Namibia
22nd Jul 20154:15 pmRNSIssue of Equity
21st Jul 20157:00 amRNSAdditional placing
17th Jul 20157:00 amRNSPlacing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.